Stockscreener 앱 받기
4.54
1.73%
-0.08
시간 외 거래:
4.63
0.09
+1.98%
Atara Biotherapeutics Inc 주식(ATRA)의 최신 뉴스
Analyst Calls: Can Ligand Pharmaceuticals Incorporated beat the S P 5002025 Price Momentum & Trade Opportunity Analysis - baoquankhu1.vn
Aug Summary: Will HAFN benefit from green energy policiesStock Surge & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
(ATRA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Atara Bio director Huang James sells $489k in shares By Investing.com - Investing.com South Africa
Atara Bio director Huang James sells $489k in shares - Investing.com
Aug Selloffs: Is Atara Biotherapeutics Inc being accumulated by smart moneyTrade Exit Summary & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel - FinancialContent
Entry Recap: Is Atara Biotherapeutics Inc stock dividend yield sustainableJuly 2025 Retail & Daily Profit Maximizing Tips - Bộ Nội Vụ
Canaccord Genuity Downgrades Atara Biotherapeutics (ATRA) to Hol - GuruFocus
Atara Biotherapeutics downgraded to Hold from Buy at Canaccord (earlier) - TipRanks
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Atara receives FDA complete response letter for Ebvallo BLA application - Pharmaceutical Business review -
FDA rejects Atara’s tabelecleucel application in surprise reversal By Investing.com - Investing.com Nigeria
Atara Biotherapeutics Stock Falls After FDA CRL On EBVALLO BLA - RTTNews
FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain - TipRanks
FDA rejects Atara’s tabelecleucel application in surprise reversal - Investing.com
Atara Biotherapeutics (ATRA) Shares Plunge After FDA Setback - GuruFocus
Atara plummets on FDA Complete Response Letter for tabelecleucel - Seeking Alpha
ATRA Stock Nearly Halves In Value After FDA Refuses Approval For Immunotherapy: Retail Sees ‘Big Fight Back’ - Asianet Newsable
Gold Rises Sharply; Lyra Therapeutics Shares Plunge - Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
FDA Hits Atara Biotherapeutics’ T-Cell Immunotherapy Tabelecleucel for EBV+ PTLD With Second CRL - CGTLive®
Atara, Pierre Fabre allege FDA about-face as agency hands down 2nd Ebvallo snub - Fierce Pharma
Why Is Atara Biotherapeutics Stock Sinking Monday?Atara Biotherapeutics (NASDAQ:ATRA) - Benzinga
US FDA declines to approve Atara's therapy for rare blood cancer - Reuters
Atara Biotherapeutics stock dives on FDA EBVALLO rejection — what ATRA investors watch next - TechStock²
FDA Rejects Atara's (ATRA) Ebvallo BLA: Calls for New Evidence o - GuruFocus
US FDA declines to approve Atara’s therapy for rare blood cancer - PharmaLive
Atara's cell therapy is again rejected by FDA, cites agency reversing position on single-arm study - Endpoints News
FDA says unable to approve Atara Biotherapeutics Ebvallo BLA in present form - TipRanks
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy By Investing.com - Investing.com UK
Atara Biotherapeutics stock plunges after FDA rejects cancer therapy - Investing.com
FDA says no to rare transplant cancer treatment patients awaited - Stock Titan
Atara Biotherapeutics Provides Regulatory and Business Update on EBVALLO™ (tabelecleucel) - Business Wire
Atara revises tab-cel commercialization milestones with Pierre Fabre - MSN
Atara Biotherapeutics (NASDAQ:ATRA) Shares Down 21.6%What's Next? - MarketBeat
Why Atara Biotherapeutics Inc. stock could be next big winnerJuly 2025 Sentiment & Weekly High Conviction Ideas - Улправда
Why Atara Biotherapeutics Inc. stock is a value investor pickWeekly Trading Summary & Low Risk High Win Rate Picks - Улправда
Is Atara Biotherapeutics Inc. stock safe for conservative investorsProfit Target & Low Risk High Reward Ideas - Улправда
Why Atara Biotherapeutics Inc. stock attracts global investorsEarnings Trend Report & Risk Controlled Swing Alerts - ulpravda.ru
Atara Stock Plunges To 3-Month Low After FDA Blocks Blood Cancer Drug: Retail's Buying The Dip - MSN
Atara Biotherapeutics prices $16M public offering - MSN
Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears - TipRanks
How Atara Biotherapeutics Inc. stock performs in interest rate cyclesMarket Volume Summary & Fast Moving Stock Trade Plans - Улправда
FDA Decisions to Look For in 1H 2026 - CGTLive®
สล็อตเว็บตรง www.offroadpakistan.com - Early Times
(ATRA) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Atara Biotherapeutics IncEntered fourth amendment with Pierre FabreSEC filing - marketscreener.com
Weekly Analysts’ Ratings Changes for Atara Biotherapeutics (ATRA) - Defense World
How Atara Biotherapeutics Inc. stock performs in stagflationHead and Shoulders Patterns & Easy Tools to Analyze Your Investment Risk - bollywoodhelpline.com
Atara Bio director Huang James sells $489k in shares _newTouch_By Investing.com - Investing.com Nigeria
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
Biotech Stocks Facing FDA Decision In January 2026 - RTTNews
Can Atara Biotherapeutics Inc. stock deliver consistent earnings growthShort Interest Overview & Superior Trading Portfolio - bollywoodhelpline.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
4.73%
0.92%
자본화:
|
볼륨(24시간):